Honorable Tom Oliverson, Chair, House Committee on Insurance
FROM:
Jerry McGinty, Director, Legislative Budget Board
IN RE:
HB3922 by Oliverson (relating to information provided by health care providers and hospitals to certain patients regarding pharmaceutical manufacturer patient assistance programs for insulin.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
The bill would require health care providers and hospitals that receive uncompensated care pool payments to provide a patient diagnosed with diabetes who requires insulin information regarding the availability of pharmaceutical manufacturer patient assistance programs that may reduce the cost of insulin to the patient. The Health and Human Services Commission indicates it could absorb the costs associated with the bill within current resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies:
304 Comptroller of Public Accounts, 529 Hlth & Human Svcs Comm